Your fact-checks will appear here
Ivermectin combined with immune checkpoint inhibitors for cancer treatment, specifically in metastatic triple-negative breast cancer
Two registered early‑phase clinical trials combine ivermectin with immune checkpoint inhibitors for cancer: a phase I/II investigator‑initiated trial testing oral ivermectin with balstilimab (and an e...
Standard single-dose antiparasitic regimens of oral ivermectin produce plasma levels in the low nanomolar range, whereas multi‑day oncology schedules being tested raise both total exposure and peak le...
Clinical testing of ivermectin in cancer patients remains nascent: searches of the clinical literature and trial registries identify essentially one active early-phase trial combining ivermectin with ...
A small number of published reports flag concomitant use of statins in patients who developed neurological adverse events after ivermectin, but the evidence is limited to case-series mentions and phar...
ABCB1 (P‑glycoprotein, P‑gp) functions as a powerful efflux pump at the blood–brain barrier that normally prevents ivermectin accumulation in the CNS, so loss or inhibition of P‑gp permits large incre...
P‑glycoprotein (P‑gp, ABCB1/MDR1) at the blood–brain barrier is the primary efflux transporter that prevents ivermectin from accumulating in the central nervous system by actively pumping the drug bac...
Ivermectin is primarily metabolized by hepatic CYP3A4 and is eliminated mostly in feces, so coadministration with other liver‑metabolized drugs or hepatic impairment can alter exposure and risk of tox...